Skip to main content

Advertisement

Table 1 Ongoing studies with Metmb (onartuzumab)

From: Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities

NCT Number Combination Drugs PHASES URL
NCT01897038 Drug: Onartuzumab Phase1 https://ClinicalTrials.gov/show/NCT01897038
Drug: Sorafenib
NCT01519804 Drug: Placebo Phase2 https://ClinicalTrials.gov/show/NCT01519804
Drug: cisplatin/carboplatin
Drug: onartuzumab
Drug: paclitaxel
NCT00854308 Drug: Erlotinib HCl Phase2 https://ClinicalTrials.gov/show/NCT00854308
Drug: MetMAb
Drug: placebo (0.9% saline)
NCT01496742 Drug: Placebo Phase2 https://ClinicalTrials.gov/show/NCT01496742
Drug: RO5490258
Drug: bevacizumab [Avastin]
Drug: cisplatin/carboplatin
Drug: paclitaxel
Drug: pemetrexed
NCT02031744 Drug: erlotinib [Tarceva] Phase3 https://ClinicalTrials.gov/show/NCT02031744
Drug: Placebo
Drug: Onartuzumab [MetMAb]
NCT01887886 Drug: erlotinib Phase3 https://ClinicalTrials.gov/show/NCT01887886
Drug: onartuzumab
Drug: placebo
NCT01456325 Drug: Erlotinib Phase 3 https://ClinicalTrials.gov/show/NCT01456325
Drug: Onartuzumab (MetMab)
Drug: Placebo